{"name":"Renalytix","slug":"renalytix","ticker":"RNLX","exchange":"NASDAQ","domain":"renalytix.com","description":"Renalytix is a diagnostics company focused on kidney health, utilizing AI and machine learning to develop innovative solutions. The company's top products include KidneyIntelX, a diagnostic test for kidney disease. Renalytix has established a strong market position in the nephrology sector.","hq":"New York, NY","founded":2019,"employees":"~350","ceo":"James McCullough","sector":"Diagnostics / AI / Nephrology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"1.3B","metrics":{"revenue":5000000,"revenueGrowth":-32.7,"grossMargin":0,"rdSpend":0,"netIncome":-33456000,"cash":7972000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Renalytix Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Renalytix reported revenue of $13.4 million for the fourth quarter and $44.4 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Renalytix Announces Collaboration with AstraZeneca to Develop Kidney Disease Diagnostic Test","summary":"Renalytix partnered with AstraZeneca to develop a diagnostic test for kidney disease using KidneyIntelX.","drugName":"","sentiment":"positive"},{"date":"2023-08-15","type":"regulatory","headline":"Renalytix Receives FDA Clearance for KidneyIntelX","summary":"The FDA cleared KidneyIntelX for use in diagnosing kidney disease.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPVVdVSWFrY0szbzNLUGFpdl9yNk9CM0dRQkpwZjdXTFA0MHlYSVZndk5ZcDdDUFdqa3dMVmk3ek41Ni02NlEzUHBxOGZ0WXpUZGFEZHBQOTh3cHZKX2xjTG8xcjhsWU5Za01HYUxtQ0ZVOXZHWHloUExOQlVxeVBKNEFDbVdqVExTV2xGX3RjMGV4ZjRPa3lwV1Z3TDNGcnJZcnRSeU1UeldXdlJjNGRIRlZod3JwQlM4Y0E?oc=5","date":"2021-09-14","type":"pipeline","source":"InvestorPlace","summary":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday - InvestorPlace","headline":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["AstraZeneca","Abbott Laboratories","Siemens Healthineers"],"therapeuticFocus":["Nephrology","Diagnostics"],"financials":{"source":"sec_edgar","revenue":2289000,"revenuePeriod":"2024-06-30","revenueHistory":[{"value":2289000,"period":"2024-06-30"},{"value":3403000,"period":"2023-06-30"},{"value":3403000,"period":"2023-06-30"},{"value":2970000,"period":"2022-06-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-33456000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":7972000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}